Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

after the call.

To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

The teleconference replay will be available approximately three hours after the call. The teleconference replay will be available for 10 business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 95970767. The webcast will remain available on the company's website until the next earnings call.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has an R&D portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes pirfenidone for which a Phase 3 program in patients with IPF (CAPACITY) has been completed and the compound is currently in the pre-registration stage. The company also has a research program focused on a pirfenidone analog named ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in the summer of 2009 and a second-generation HCV protease inhibitor research program. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without lim
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Toronto, Canada (PRWEB) July 10, 2014 ... often present in very low abundance and are ... quite challenging and time-consuming. , Join presenters Dr. ... Laboratories, and Dr. John Anders, Head of Quality ... mass spectrometer-based approach that can speed detection and ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Robert Harman, ... Veterinary Medicine company, is proud to announce the relaunch of ... launching with a new series called “ What are Stem ... give an honest and straightforward foundation in the basics of ... educated decision on the right type of treatment when considering ...
(Date:7/10/2014)... On July 9 Prime Minister ... Russia,s first national "Industry" award ... is developing a unique project called MabNext . ... number of innovative drugs based on monoclonal antibodies for ... place at the International Exhibition "Innoprom 2014" in Ekaterinburg. ...
(Date:7/10/2014)... 2014 -- According to the International Atomic Energy ... comes from terrorists acquiring sufficient quantities of plutonium ... crude nuclear explosive device. The IAEA also notes ... involved gram-level quantities, which can be challenging to ... a new study appearing this week in the ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Sensitive detection method may help impede illicit nuclear trafficking 2
... WASHINGTON , May 20 Today, world-renowned ... and his team at the J. Craig Venter Institute (JCVI) ... self-replicating cell.  The news holds groundbreaking potential for solutions to ... pharmaceuticals and vaccines; cleaning up pollution; creating new energy sources; ...
... ... University of California campuses -- San Francisco and Berkeley -- to jointly launch the first ... patient care. , ... 20, 2010 -- Former Intel Corp. chief executive Andy Grove has pledged $1.5 million to ...
... SAN FRANCISCO and WASHINGTON , ... Inc., a clinical-stage cancer biotherapeutics company, today reported positive ... the intravenous (IV) administration of JX-594 to patients with ... delivery to solid tumors, cancer-targeted replication and gene expression, ...
Cached Biology Technology:Science Channel Announces the Debut of Exclusive Look Into Dr. J. Craig Venter's Creation of Synthetic Life 2Science Channel Announces the Debut of Exclusive Look Into Dr. J. Craig Venter's Creation of Synthetic Life 3Grove Gift Launches Translational Medicine Program at UCSF & UC Berkeley 2Grove Gift Launches Translational Medicine Program at UCSF & UC Berkeley 3Grove Gift Launches Translational Medicine Program at UCSF & UC Berkeley 4Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously 2Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously 3Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously 4
(Date:7/11/2014)... Tenn., July 11, 2014--Researchers at the Department of ... R&D 100 awards, presented by R&D Magazine in ... , "These awards recognize the tremendous value of ... Moniz. "Research and development at the National Labs ... challenges and pursue the scientific and technological innovations ...
(Date:7/11/2014)... German . ... refraction of X-rays through a specimen instead of attenuation ... are often of much higher quality than those based ... Franz Pfeiffer are particularly interested in developing new approaches ... phase-contrast imaging. One main goal is to make this ...
(Date:7/11/2014)... develop relationships with other group members to reduce aggression ... baboons the strategy for grooming activities shows a certain ... in the scientific journal Biology Letters . , ... not practiced without ulterior motives. To be groomed has ... while grooming another individual can provide access to infants, ...
Breaking Biology News(10 mins):ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4New simple setup for X-ray phase contrast 2Baboons groom early in the day to get benefits later 2
... can complicate treatment after many surgical procedures. In ... found in many healthcare settings, can be a ... the April issue of the American Journal of ... of 12 patients after refractive surgery. , These ...
... to weigh less than children who sleep less, and ... overweight five years later. That’s one of the major ... 2007 issue of the journal Child Development. , Conducted ... 2,281 children from a nationally representative survey called the ...
... $22.5 million research program at Iowa State University ... The grant is part of ConocoPhillips' plan to ... produce viable solutions to diversify America's energy sources. ... million grant in 2007 to support Iowa State ...
Cached Biology News:Drug-resistant bacterial infections serious complication after corrective eye surgery 2Children who sleep more weigh less 2ConocoPhillips establishes $22.5M biofuels research program at Iowa State 2ConocoPhillips establishes $22.5M biofuels research program at Iowa State 3
... plus assay system offers the ... Designed for batch-processing systems, Long ... density microplates such as 384-well ... Convenient storage conditions ( 2 ...
... kit consists of universal lysis buffer, PCR ... for 100 25 l volume PCR reactions. ... Gram negative or positive rod and coccus ... Bacillus Cereus, Staphylococcus Aureus, Streptococcus Agalactiae, and ...
... The SilverQuest Silver Staining Kit ... silver staining sensitivity with minimal protein ... The mass spectrometry problems associated with ... the SilverQuest kit because the reagents ...
...
Biology Products: